Singapore biomedical R&D spending slips despite strong govt commitment
This article was originally published in Scrip
Singapore's multi-pronged effort to position itself as "Asia's Innovation Capital" bore fruit last year, when the island state saw a double-digit rise in gross R&D expenditure across the public and private sectors.
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.